Development of a Δ glnA Balanced Lethal Plasmid System for Expression of Heterologous Antigens by Attenuated Vaccine Vector Strains of Vibrio cholerae
Open Access
- 1 January 2000
- journal article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 68 (1) , 221-226
- https://doi.org/10.1128/iai.68.1.221-226.2000
Abstract
We have previously shown that more prominent immune responses are induced to antigens expressed from multicopy plasmids in live attenuated vaccine vector strains of Vibrio cholerae than to antigens expressed from single-copy genes on the V. cholerae chromosome. Here, we report the construction of a Δ glnA derivative of V. cholerae vaccine strain Peru2. This mutant strain, Peru2Δ glnA , is unable to grow on medium that does not contain glutamine; this growth deficiency is complemented by pKEK71- Not I, a plasmid containing a complete copy of the Salmonella typhimurium glnA gene, or by pTIC5, a derivative of pKEK71- Not I containing a 1.8-kbp fragment that directs expression of CtxB with a 12-amino-acid epitope of the serine-rich Entamoeba histolytica protein fused to the amino terminus. Strain Peru2Δ glnA (pTIC5) produced 10-fold more SREHP-12-CtxB in supernatants than did ETR3, a Peru2-derivative strain containing the same fragment inserted on the chromosome. To assess immune responses to antigens expressed by this balanced lethal system in vivo, we inoculated germfree mice on days 0, 14, 28, and 42 with Peru2Δ glnA , Peru2Δ glnA (pKEK71- Not I), Peru2(pTIC5), Peru2Δ glnA (pTIC5), or ETR3. All V. cholerae strains were recoverable from stool for 8 to 12 days after primary inoculation, including Peru2Δ glnA ; strains containing plasmids continued to harbor pKEK71- Not I or pTIC5 for 8 to 10 days after primary inoculation. Animals were sacrificed on day 56, and serum, stool and biliary samples were analyzed for immune responses. Vibriocidal antibody responses, reflective of in vivo colonization, were equivalent in all groups of animals. However, specific anti-CtxB immune responses in serum ( P ≤ 0.05) and bile ( P ≤ 0.001) were significantly higher in animals that received Peru2Δ glnA (pTIC5) than in those that received ETR3, confirming the advantage of higher-level antigen expression in vivo. The development of this balanced lethal system thus permits construction and maintenance of vaccine and vector strains of V. cholerae that express high levels of immunogenic antigens from plasmid vectors without the need for antibiotic selection pressure.Keywords
This publication has 42 references indexed in Scilit:
- Initial Clinical Studies of CVD 112 Vibrio cholerae O139 Live Oral Vaccine: Safety and Efficacy against Experimental ChallengeThe Journal of Infectious Diseases, 1995
- Development Of A Live, Oral, Attenuated Vaccine Against El Tor CholeraThe Journal of Infectious Diseases, 1994
- Emergence of a New Cholera Pandemic: Molecular Analysis of Virulence Determinants in Vibrio cholerae 0139 and Development of a Live Vaccine PrototypeThe Journal of Infectious Diseases, 1994
- Use of the Vibrio cholerae irgA gene as a locus for insertion and expression of heterologous antigens in cholera vaccine strainsVaccine, 1993
- Isogenic P‐fimbrial deletion mutants of pyelonephritogenic Escherichia coli: the role of α Gal(1–4)β Gal binding in virulence of a wild‐type strainMolecular Microbiology, 1993
- Intestinal immune responses in humans. Oral cholera vaccination induces strong intestinal antibody responses and interferon-gamma production and evokes local immunological memory.Journal of Clinical Investigation, 1991
- Allelic exchange in Escherichia coli using the Bacillus subtilis sacB gene and a temperature‐sensitive pSC101 repliconMolecular Microbiology, 1991
- SAFETY, IMMUNOGENICITY, AND EFFICACY OF RECOMBINANT LIVE ORAL CHOLERA VACCINES, CVD 103 AND CVD 103-HgRThe Lancet, 1988
- Cholera toxin genes: nucleotide sequence, deletion analysis and vaccine developmentNature, 1983
- Duration of Infection-Derived Immunity to CholeraThe Journal of Infectious Diseases, 1981